Novel combination therapy using IL-33 and Anti-Areg Antibodies Decreases Tumor Growth
University of Pittsburgh researchers have demonstrated through their studies that an anti-Areg antibody and IL-33 synergistically inhibited tumor growth. Pitt’s research establishes that Areg/EGFR is required for maintaining immune suppression during IL-33 immunotherapy IL-33, a human protein encoded in the IL33 gene, shows strong antitumor activities. IL-33 can also be combined with immune checkpoint inhibitors (ICIs) to further augment antitumor efficacy. Because IL-33 plays a multifaceted role in tumor immunity, its antitumor efficacy is limited, which makes it essential to define the underlying cellular networks of IL-33-driven tumoral immune responses.